RE:Comparing short positions CXR and CXRXEveryone thought the shorts were crazy to be shorting at the $30-35 level and people were talking about what great value it was. Here we are in the $11s and the shorts are planning on riding it to $0. The well respected ceo of Knight Therapeudics expected there was going to be some fire sale assets to buy cheaply early next year as conveyed on a recent conference call. One can assume Concordias will be amongst them. The shorts knew cxr was going to run into an awful lot of trouble or they wouldnt have taken such large positions. If it was so clear to investors, how in the world did this management team not see it coming as the "business was firing on all cylinders." So what comes next... Does their main drug get pulled due to lack of fda approval or pricing pressure in US or Uk further cuts cashflows already on the razors edge. What could be a possible catalyst? They don't seem to have the money for r&d for another fda approval on anything and i dont expect they can buy anymore assets to offset declines on assets they already overpaid and overleveraged for. Seems it will be in a death spiral until its sold for parts and the only ones who will get scraps are bondholders. I dont see a short squeeze happening because they can be patient and likely never have to cover. Happy trading!